New combo vaccine aims to shield teens from five types of meningitis
NCT ID NCT05087056
First seen Apr 15, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This study is testing a new vaccine called MenABCWY that protects against five groups of bacteria that cause meningitis, a serious infection around the brain and spine. About 312 healthy teenagers will receive the vaccine on different schedules to see how safe it is and how well it boosts their immune system. The goal is to find the best way to give this combined shot to prevent meningitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGITIS, MENINGOCOCCAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Tucson, Arizona, 85745, United States
-
GSK Investigational Site
Ventura, California, 93003, United States
-
GSK Investigational Site
Macon, Georgia, 31210, United States
-
GSK Investigational Site
Valparaiso, Indiana, 84088, United States
-
GSK Investigational Site
Missoula, Montana, 80216, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28226, United States
Conditions
Explore the condition pages connected to this study.